The preclinical development of biotechnology-derived pharmaceuticals: the PMA perspective. Pharmaceutical Manufacturers Association.
作者信息
Stoll R E
出版信息
Prog Clin Biol Res. 1987;235:169-71.
PMID:3474669
Abstract
摘要
相似文献
1
2
Preclinical safety evaluation of monoclonal antibodies.单克隆抗体的临床前安全性评估
Handb Exp Pharmacol. 2008(181):19-44. doi: 10.1007/978-3-540-73259-4_2.
3
Safety evaluation of biotechnology derived products.生物技术衍生产品的安全性评估。
Prog Clin Biol Res. 1987;235:3-14.
4
Biotech pharmaceuticals and biotherapy: an overview.生物科技制药与生物疗法：概述
J Pharm Pharm Sci. 1998 May-Aug;1(2):48-59.
5
Preclinical safety evaluation of pharmaceuticals for the world market.面向全球市场的药品临床前安全性评估。
Aust J Biotechnol. 1990 Jan;4(1):43-5.
6
Genetically engineered drugs: toxicology with a difference.基因工程药物：与众不同的毒理学。
Prog Clin Biol Res. 1987;235:161-7.
7
Biotechnology products intended for human use, toxicological targets and research strategies.用于人类的生物技术产品、毒理学靶点及研究策略。
Prog Clin Biol Res. 1987;235:143-59.
8
9
Preclinical and clinical development of immunocytokines.免疫细胞因子的临床前和临床开发。
Curr Opin Investig Drugs. 2003 Jun;4(6):696-700.
10
Preclinical safety evaluation of recombinant human interleukin-10.重组人白细胞介素-10的临床前安全性评估
Regul Toxicol Pharmacol. 2002 Feb;35(1):56-71. doi: 10.1006/rtph.2001.1504.
Zotero 插件